

## **Santen Announces Drug Discovery and Development Agreement with PeptiDream**

September 25, 2018 - Santen Pharmaceutical Co., Ltd. (Osaka, Japan, Chairman & CEO: Akira Kurokawa, hereafter Santen) today announced that it has entered into a broad-based multi-target discovery and development agreement with PeptiDream Inc., (Kanagawa, Japan, hereafter PeptiDream). Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple ophthalmic disease targets of interest selected by Santen, and to optimize hit peptides into therapeutic peptides products for such indications. PeptiDream will be responsible for drug discovery and part of preclinical development aspects, while Santen will be responsible for preclinical and clinical development of identified candidates. Santen is a specialized pharmaceutical company with a focus on ophthalmology, a disease area to which PeptiDream's constrained peptides have the potential to become ideal therapeutics.

“With this partnership, Santen intends to strengthen and broaden its ability to address unmet needs. In addition to biologics and small molecules, we will now have access to promising new constrained peptides to manage ocular pathologies,” said Naveed Shams, M.D., Ph.D., Chief Scientific Officer and Head of Global R&D at Santen.

Under the terms of the agreement, Santen would pay an undisclosed upfront payment and research funding to PeptiDream. For the future, Santen would pay preclinical, clinical and commercialization milestone payments and royalties on sales of any products that arise from the collaboration to PeptiDream.

### **Contact**

Santen Pharmaceutical Co., Ltd.

Christopher Hohman, General Manager, Corporate Communications Group

E-mail: [ir@santen.com](mailto:ir@santen.com) Tel: +81-6-4802-9360

**About PeptiDream Inc.**

PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit [www.peptidream.com](http://www.peptidream.com).

**About Santen Pharmaceutical Co., Ltd. (Head Office: Osaka, Japan)**

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website ([www.santen.com](http://www.santen.com)).